2010 MSG Annual Meeting
The Muscle Study Group held its annual meeting on September 20-22, 2010 at Beaver Hollow Conference Center, Java Center, NY.
The agenda included five major sessions: The Challenges of Patient Recruitment, Recruiting the Next Generation of NMD Investigators, Inflammatory Myopathies: Pathogenesis, Treatment and Clinical Trials, Inflammatory Myopathies: Pathogenesis, Treatment and Clinical Trials (Continued), and Past, Current and Future Protocols: Lessons Learned.
The meeting was sponsored by:
- National Institutes of Health, Grant #1R13NS071695-01:
- National Institute of Neurological Disorders and Stroke (NINDS)
- Office of the Director (OD)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Muscular Dystrophy Association
- ISIS Pharmaceuticals
- PTC Therapeutics
Presentations
The Muscle Study Group received permission to post these presentations online:
Myositis Patient Registry – Bob Goldberg
FOR-DMD Steroid Trial – Robert Griggs
European Perspective on Recruitment – Michael Hanna
Update from British Myology Society – Michael Hanna
Young Neurologists in the Basic Library – Ahmet Hoke
NIH Report on Support for Research on Neuromuscular Diseases – Glen Nuckolls
IMACS History and Development – Chester Oddis
Abstracts
The Muscle Study Group received permission to post the following abstracts online:
Safety and Feasibility of Transvenous Limb Profusion with Saline in Human Muscular Dystrophy – James Howard
Mechanism of Axonal Degeneration in Drosophilia Model of Distal SBMA – Thomas Lloyd
Reproductability and Reliability of Quantitative MRI Measures for Neuromuscular Disease – Jasper Morrow
Clinical Improvement and Decreased Peripheral Autoreactivity in Refractory Myasthenia Gravis Treated with Rituximab – Richard Nowak
A Therapy for Duchenne Dystrophy Based Upon Inhibition of Mechanically Sensitive Ion Channels – Frederick Sachs
Inherited Neuropathies Consortium – Carly Siskind
2009 MSG Annual Meeting
The MSG held its annual meeting on September 21-23, 2009 at Beaver Hollow, Java Center, NY.
The meeting, entitled “Fostering Pharma-Academic Partnerships in Neuromuscular Experimental Therapeutics,” brought together members of the pharmaceutical industry and academic researchers.
The agenda included two major sessions: (1) Novel designs and outcome measures in translational neuromuscular research and (2) scientific updates in basic science, methods and treatment strategies.
The meeting was sponsored by:
- National Institutes of Health:
- National Institute of Neurological Disorders and Stroke (NINDS)
- Office of the Director (OD)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Muscular Dystrophy Association
- ISIS Pharmaceuticals
- PTC Therapeutics
- Santhera Pharmaceuticals
Presentations
The MSG received permission to post these presentations online:
The Peripheral Nerve Study Group – Its Rise and Demise – Arthur Asbury
Treatment of Neuromuscular Diseases With Antisense Oligonucleotides – Frank Bennett
FOR-DMD – Kate Bushby
MSG – Past, Present, Future – Robert Griggs
HYP-HOP – Robert Griggs
The SMA Project – Jill Heemskerk
High Dose Vitamin C Treatment of CMT CMT-1A – Richard Lewis
Dermal Nerve Assessment: A Window to the Mechanism of Neuropathies in Outcome Measures – Jun Li
The Challenges of Conducting Clinical Development in Rare/Orphan Diseases: The Industry Perspective – Thomas Meier
Attaining Symbiosis in Therapy Development Efforts in NMDs – John Porter
Trial Design and Outcomes for Inherited Neuropathy Network – Davide Pareyson
Abstracts
The MSG received permission to post the following abstracts online:
TREAT-NMD and the ICC: A Fruitful Collaboration to Foster Clinical Trials and Research in SMA – Anna Ambrosini
Using Video Gait Analysis to Assess Gait Dysfunction in Duchenne Muscular Dystrophy: A Pilot Study – Yaacov Anziska
Use of the 6-Minute Walk Test to Assess Potential Drug Effects of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy – Leone Atkinson
Mechanostat theory used to understand bone complications in children with Duchenne muscular dystrophy – Craig Campbell
Sparing of Myofiber Membranes in Infantile Pompe’s Disease – Ludwig Gutman
Clinical Development of idebenone (CATENA) for the treatment of Duchenne Muscular Dystrophy – A summary of Phase II study results and design of a Phase III clinical study – Thomas Meier
The challenges of conducting clinical development in rare/orphan diseases – The industry perspective – Thomas Meier
Diagnosis of Pompe Disease: Timing and Methods Used as Reported to the Pompe Registry – Tim Miller
Fatty Acid Oxidation Disorders in Adults: A potentially treatable case of muscle disease – Robert Pitceathly
Presence and Nature of “Tau” Immunoreactivity in Normal Myonuclei and Inclusion Body Myositis – Mohammad Salajegheh
Initial Results from Single Subcutaneous Administration of ACE-031, a Form of the Soluble Activin Type IIB Receptor, in Healthy Postmenopausal Volunteers – Jasbir Seehra
2008 MSG Annual Meeting
The MSG held a meeting of clinical scientists on September 15-17, 2008 at Beaver Hollow, Java Center, NY, entitled “Experimental Therapeutics of Neuromuscular Disease.” The conference brought together translational and clinical scientists in a forum for discussion of current and novel therapies and drew speakers and participation from international experts with an interest in developing international collaborations among trainees and investigators focused on clinical trials. Specific to international collaboration many members of the TREAT-NMD consortium based in Europe attended the meeting, thereby fostering connections necessary to facilitate clinical trials in the rare diseases.
The agenda included two major sessions: (1) Novel designs and outcome measures in translational neuromuscular research and (2) scientific updates in basic science, methods and treatment strategies.
The meeting was sponsored by:
- National Institutes of Health:
- National Institute of Neurological Disorders and Stroke (NINDS)
- Office of the Director (OD)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Muscular Dystrophy Association
- Acceleron Pharma
Presentations
The MSG received approval to post the following presentations online:
Ocular MG – Michael Benatar
Sleuthing Targets for Disease in Muscle – Andrew Engel
Clinical Investigation of Neurological Channelopathies (CINCH) Landmarks – Robert C. Griggs
HYP HOP – Robert C. Griggs
Clinical Trials: From Inception to Implementation – Laura Herbelin
Trial Implementation Strategies – Cornelia Kamp
Clinical Materials Services Unit (CMSU) – Cornelia Kamp
Iplex Treatment of Myotonic Dystrophy – Richard T. Moxley III
High Dose Ascorbic Acid to Treat CMT1A – Michael Shy
MSG 2007 Annual Meeting
Through the funding of an NIH R13 award, the MSG held a meeting of clinical scientists on September 17-19, 2007, at Beaver Hollow, Java Center, NY. The program emphasized translational approaches to bringing molecular discoveries into well-designed clinical studies.
The agenda included two major sessions: (1) Novel designs and outcome measures in translational neuromuscular research and (2) scientific updates in basic science, methods and treatment strategies.
MSG 2006 Annual Meeting
Through the funding of an NIH R13 award, the MSG held a meeting of clinical scientists on May 31 through June 2, 2006 at Beaver Hollow, Java Center, NY. The program emphasized translational and experimental therapeutics research.
The agenda included two major sessions: (1) Translational bench-to-bedside presentations on topics including muscular dystrophy, neuromuscular junction disorders and motor neuron disorders and (2) Clinical trial methodology session including industry, FDA and academic perspectives.
